Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31136489 | 0.93 | MAPT (0.54) | BCHEACHEBACE1HPGDMAPT | |
| SCHEMBL30523671 | 0.87 | OPRL1 (0.54) | BCHEACHEBACE1MAPTP2RX7 | |
| SCHEMBL22361700 | 0.87 | OPRL1 (0.54) | BCHEACHEBACE1MAPTP2RX7 | |
| SCHEMBL951982 | 0.84 | SLC6A2 (0.49) | BCHEACHEBACE1MAPTP2RX7 | |
| SCHEMBL951983 | 0.84 | SLC6A2 (0.49) | BCHEACHEBACE1MAPTP2RX7 | |
| SCHEMBL30802465 | 0.82 | BCHE (0.63) | BCHEACHEBACE1P2RX7 | |
| SCHEMBL694951 | 0.82 | BCHE (0.65) | BCHEACHEBACE1HPGDMAPT | |
| SCHEMBL23124460 | 0.79 | GRM2 (0.48) | BCHEACHEBACE1HPGDMAPT | |
| SCHEMBL23105979 | 0.79 | BCHE (0.47) | BCHEACHEBACE1HPGDMAPT | |
| SCHEMBL4482088 | 0.77 | OPRL1 (0.53) | BCHEACHEBACE1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012085935-A2 | COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-06-28 | — | — | WO | disclosed |
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | BCHE 1870/4885ACHE 1313/4885BACE1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.